Company intelligence / Profile preview
Agennix AG
Martinsried/Munich, Bavaria, Germanyagennix.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Agennix was a publicly traded German-American biopharmaceutical company focused on developing novel therapies for oncology and critical care. Its lead program was oral talactoferrin, a first-in-class dendritic cell-mediated immunotherapy that reached Phase III trials in non-small cell lung cancer but failed to meet endpoints. Other programs included multi-targeted kinase inhibitors and topical biologics. The company ceased operations following multiple late-stage clinical trial failures by mid–2013.
- Therapeutic areas
- OncologyEndocrinologyInfectious Diseases
- Modalities
- Small molecules (e.g., satraplatin, RGB compounds)Monoclonal antibodies (e.g., MAb 1D09C3)Recombinant proteins/biologics (talactoferrin is a recombinant protein immunotherapy)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Yakult Honsha Co. Ltd. — partnership over satraplatin development in Japan.
Beyond the preview
Go deeper on Agennix AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agennix AG.